Erasca prioritizes pipeline, extends cash runway to H1 2026; FDA/EMA agree on Phase 3 naporafenib trial

Erasca, Inc.

FDA/EMA endorsed SEACRAFT-2 Phase 3 design for naporafenib+trametinib in NRASm melanoma; dual primary endpoints PFS and OS.
Phase 1 data for ERAS-801 in rGBM: MTD 240 mg QD, safe, PK above 90% tumor growth inhibition; expansion cohorts enrolling.
Deprioritized FLAGSHP-1 (ERAS-601+cetuximab), ERAS-5, ERAS-10; cash runway extended from H2 2025 to H1 2026.
Key upcoming milestones: naporafenib Phase 1b data in RAS Q61X tumors (2H 2024), ERAS-007 combo data in BRAFm CRC (H2 2023–H1 2024).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.